{"schema_version":"secwatch.filing_event.v1","accession":"0001093557-24-000003","form_type":"8-K","ticker":"DXCM","cik":"0001093557","company_name":"DEXCOM INC","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.342985+00:00","generated_at":"2026-06-07T01:58:03.174242+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"DexCom reports preliminary Q4 revenue ≥$1.03B (+26% YoY); FY2024 guidance $4.15-4.35B","bullets":["Preliminary Q4 2023 revenue at least $1.030B, up 26% YoY; FY2023 revenue ~$3.62B (+24%).","FY2024 revenue guidance $4.15-4.35B, representing organic growth of 16-21%.","Non-GAAP gross profit margin guidance 63-64% for FY2024; operating margin ~20%.","Submitted Stelo glucose sensor for type 2 non-insulin users to FDA; expected U.S. launch summer 2024.","U.S. Q4 revenue ~$765M (+26% YoY); international ~$265M (+27% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001093557-24-000003","json":"https://secwatch.observer/filing/0001093557-24-000003.json","markdown":"https://secwatch.observer/filing/0001093557-24-000003.md","text":"https://secwatch.observer/filing/0001093557-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/0001093557-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/dxcm-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:58:03.174242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79d8f84f80844b84454a1ce3de58992ae5568fd6","claim":"DEXCOM INC reported the fourth quarter ended December 31, 2023 results: revenue $1.030 billion.","evidence_excerpt":"preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 is expected to be at least $1.030 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/0001093557-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$1.030 billion"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"ce661dca8ff26400585e6ba915aac98593f9f518","claim":"DEXCOM INC reported fiscal year 2024 results: revenue $4.15 billion to $4.35 billion. Guidance initiated.","evidence_excerpt":"For 2024, Dexcom currently anticipates total revenue of approximately $4.15 billion to $4.35 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/0001093557-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2024"},{"label":"Revenue","value":"$4.15 billion to $4.35 billion"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"ced8973188440f36b8847f13851c947d030782a5","claim":"DEXCOM INC reported fiscal year 2023 results: revenue $3.62 billion.","evidence_excerpt":"For fiscal year 2023, total preliminary, unaudited revenue is expected to be approximately $3.62 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/0001093557-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"$3.62 billion"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}